The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe? DOI Creative Commons

Jingli Xu,

Yuan Li,

Yancheng Tang

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2020, Volume and Issue: 8

Published: Dec. 3, 2020

Gastric cancer is the third most common cause of cancer-related death worldwide. Drug resistance main inevitable and vital factor leading to a low 5-year survival rate for patients with gastric cancer. Autophagy, as highly conserved homeostatic pathway, mainly regulated by different proteins non-coding RNAs (ncRNAs) plays dual roles in drug Thus, targeting key regulatory nodes process autophagy small molecule inhibitors or activators has become one promising strategies treatment recent years. In this review, we provide systematic summary focusing on relationship between chemotherapy We comprehensively discuss molecular mechanisms multiple emerging ncRNAs including miRNAs lncRNAs regulation pathways chemoresistance. also summarize effects inhibitor Understanding chemoresistance will novel opportunities develop therapeutic

Language: Английский

miRNA-based biomarkers, therapies, and resistance in Cancer DOI Creative Commons
Boxue He, Zhenyu Zhao, Qidong Cai

et al.

International Journal of Biological Sciences, Journal Year: 2020, Volume and Issue: 16(14), P. 2628 - 2647

Published: Jan. 1, 2020

MicroRNAs (miRNAs), small non-coding RNAs (ncRNAs) of about 22 nucleotides in size, play important roles gene regulation, and their dysregulation is implicated human diseases including cancer.A variety miRNAs could take the cancer progression, participate process tumor immune, function with miRNA sponges.During last two decades, connection between various cancers has been widely researched.Based on evidence miRNA, numerous potential biomarkers for diagnosis prognosis have put forward, providing a new perspective screening.Besides, there are several miRNA-based therapies among different being conducted, advanced treatments such as combination synergistic strategies use complementary provide significant clinical benefits to patients potentially.Furthermore, it demonstrated that many engaged resistance complex underlying regulatory mechanisms, whose comprehensive cognition can help clinicians improve patient prognosis.With belief studies would great implications, we attempt summarize current situation development prospects this review.

Language: Английский

Citations

460
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects DOI Open Access
Rosalin Mishra, Hima Patel, Samar Alanazi

et al.

International Journal of Molecular Sciences, Journal Year: 2021, Volume and Issue: 22(7), P. 3464 - 3464

Published: March 27, 2021

The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling which mutated or amplified in wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K plays an important role cancer cell survival, angiogenesis metastasis, making it promising therapeutic target. There are several ongoing completed clinical trials involving inhibitors (pan, isoform-specific dual PI3K/mTOR) with the goal to find efficient that could overcome resistance current therapies. This review focuses on landscape various either as monotherapy combination therapies treatment outcomes involved phases different types. discussion drug-related toxicities, challenges associated these adverse events leading failure. In addition, novel drugs have potential be translated clinic highlighted.

Language: Английский

Citations

207
The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer DOI
Yu Wang, Yingying Wang,

Zhiyuan Qin

et al.

Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2021, Volume and Issue: 17(3), P. 291 - 306

Published: Feb. 7, 2021

Multi-drug resistance (MDR) is a hindrance toward the successful treatment of cancers. The primary mechanism that gives rise to acquired chemoresistance overexpression adenosine triphosphate-binding cassette (ABC) transporters. dysregulation non-coding RNAs (ncRNAs) widely concerned reason contributing this phenotype.In review, we describe role intracellular and exosomal ncRNAs including microRNAs (miRNAs), long (lncRNAs), circular (circRNAs) in ABC transporters-induced tumor MDR. Meanwhile, will introduce potential therapeutic strategies which reverse MDR terms reducing expression transporters via targeting ncRNAs, like nucleic acid delivery with nanoparticles as well miRNAs-targeted small molecular compounds.The dysregulated ncRNAs-mediated chemo-resistant cancer not negligible. Finding out underlying may provide theoretical basis for clinical therapy MDR, emergence new approaches gene suppress makes reversing possible despite its application requires further investigations. Also, discovered regulating cancers are just tip iceberg genetic transcripts, especially circRNAs, justify more concern.Abbreviations: multi-drug resistance; ABC, cassette; NcRNAs, RNAs; MiRNAs, microRNAs; LncRNAs, CircRNAs, CeRNAs, competing endogenous 3'UTR, 3'-untranslated regions; SLC, solute carrier; ABCB1/MDR1, subfamily B member 1; ABCG2/BCRP, G 2; ABCCs/MRPs, C 1 12; DLL1: Delta-like protein DTX, docetaxel; DOX/ADM/ADR, doxorubicin/adriamycin; PTX, paclitaxel; VBL, vinblastine; VCR, vincristine; MTX, methotrexate; CDDP/DDP, cisplatin/cis-diaminedichloroplatinum; OXA/L-OHP, oxaliplatin; TMZ, temozolomide; 5-FU, 5-fluorouracil; MTA, pemetrexed; NSCLC, non-small cell lung carcinoma; HCC, hepatocellular CRC, colorectal RB, retinoblastoma; RCC, renal OS, osteosarcoma; PDAC, pancreatic ductal adenocarcinoma; TNBC, triple-negative breast cancer.

Language: Английский

Citations

114
Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications DOI Creative Commons

Xuehao Zhou,

Xiang Ao,

Zhaojun Jia

et al.

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12

Published: Aug. 17, 2022

Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a serious, long-term threat to patients’ health and life. Systemic chemotherapy remains first-line therapeutic approach for recurrent or metastatic cancer patients after surgery, with potential effectively extend patient survival. However, development drug resistance seriously limits clinical efficiency ultimately results in treatment failure death. A large number studies have shown that non-coding RNAs (ncRNAs), particularly microRNAs, long RNAs, circular are widely involved regulation resistance. Their dysregulation contributes by modulating expression specific target genes cellular apoptosis, autophagy, efflux, epithelial-to-mesenchymal transition (EMT), stem cells (CSCs). Moreover, some ncRNAs also possess great as efficient, biomarkers diagnosis prognosis well targets patients. In this review, we summarize recent findings on emerging role underlying mechanisms focus their applications treatment. This information will be benefit early prognostic assessments ncRNA-based strategies

Language: Английский

Citations

79
Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update DOI Creative Commons
Emine Bayraktar, Recep Bayraktar, Hülya Öztatlıcı

et al.

Non-Coding RNA, Journal Year: 2023, Volume and Issue: 9(2), P. 27 - 27

Published: April 13, 2023

Since the discovery of first microRNAs (miRNAs, miRs), understanding miRNA biology has expanded substantially. miRNAs are involved and described as master regulators major hallmarks cancer, including cell differentiation, proliferation, survival, cycle, invasion, metastasis. Experimental data indicate that cancer phenotypes can be modified by targeting expression, because act tumor suppressors or oncogenes (oncomiRs), they have emerged attractive tools and, more importantly, a new class targets for drug development in therapeutics. With use mimics molecules (i.e., small-molecule inhibitors such anti-miRS), these therapeutics shown promise preclinical settings. Some miRNA-targeted been extended to clinical development, mimic miRNA-34 treating cancer. Here, we discuss insights into role other non-coding RNAs tumorigenesis resistance summarize some recent successful systemic delivery approaches developments anticancer development. Furthermore, provide comprehensive overview trials finally list based on miRNAs.

Language: Английский

Citations

57
Exploring the role of lncrna neat1 knockdown in regulating apoptosis across multiple cancer types: A review DOI
Md Sadique Hussain, Gaurav Gupta, Muhammad Afzal

et al.

Pathology - Research and Practice, Journal Year: 2023, Volume and Issue: 252, P. 154908 - 154908

Published: Oct. 31, 2023

Language: Английский

Citations

54
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance DOI Creative Commons
Hana Q. Sadida,

Alanoud Abdulla,

Sara Al Marzooqi

et al.

Translational Oncology, Journal Year: 2023, Volume and Issue: 39, P. 101821 - 101821

Published: Nov. 4, 2023

Cancer heterogeneity and drug resistance remain pivotal obstacles in effective cancer treatment management. One major contributor to these challenges is epigenetic modifications - gene regulation that does not involve changes the DNA sequence itself but significantly impacts expression. As we elucidate phenomena, underscore role of regulating expression, contributing cellular diversity, driving adaptive can instigate therapeutic resistance. This review dissects essential methylation, histone modifications, chromatin remodeling illustrating their significant yet complex contributions biology. While offer potential avenues for intervention due reversible nature, interplay genetic cells presents unique must be addressed harness full potential. By critically analyzing current research landscape, identify knowledge gaps propose future directions, exploring therapies discussing translating concepts into treatments. comprehensive aims stimulate further aid developing innovative, patient-centered therapies. Understanding critical scientific advancement paves way towards improving patient outcomes fight against this formidable disease.

Language: Английский

Citations

53
lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways DOI
Raed Obaid Saleh, Mushtak T.S. Al-Ouqaili,

Eyhab Ali

et al.

Medical Oncology, Journal Year: 2024, Volume and Issue: 41(2)

Published: Jan. 9, 2024

Language: Английский

Citations

22
Utilizing non-coding RNA-mediated regulation of ATP binding cassette (ABC) transporters to overcome multidrug resistance to cancer chemotherapy DOI
Kenneth K.W. To,

Zoufang Huang,

Hang Zhang

et al.

Drug Resistance Updates, Journal Year: 2024, Volume and Issue: 73, P. 101058 - 101058

Published: Jan. 19, 2024

Language: Английский

Citations

20
Up-regulation of miR-383-5p suppresses proliferation and enhances chemosensitivity in ovarian cancer cells by targeting TRIM27 DOI Open Access

Jing Jiang,

Chuanmei Xie,

Yujuan Liu

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2018, Volume and Issue: 109, P. 595 - 601

Published: Nov. 3, 2018

MicroRNAs are small non-coding RNAs which play important roles in tumor progression. MiR-383-5p has been characterized as a cancer suppressor several cancers. The aim of theses present study was to explore the role miR-383-5p proliferation and chemosensitivity ovarian cells. expression down-regulated while TRIM27 up-regulated tissues cell lines. We came up with hypothesis that might be involved progression chemoresistance through targeting TRIM27. Bioinformatics Luciferase reporter assay indicated target negatively regulated by Up-regulation found suppress decrease Ki67 PCNA cells (OVCAR3, A2780), suggesting overexpressed inhibited In addition, up-regulation decreased IC50 value paclitaxel increased apoptosis rate under treatment paclitaxel, indicating enhanced However, pcDNA3.1-TRIM27 transfection counteracted inhibitory effect on vivo experiments also revealed growth could mimic. Taken together, this lowly expressed highly cancer. proliferation, suppressing expression. Therefore, miR-383-5p/TRIM27 axis may potential for

Language: Английский

Citations

121